Precision Promise (PrP) Bayesian platform trial for metastatic pancreatic cancer (mPDAC): Results of the first experimental arm, SM-88 as second line therapy.

Authors :: Oberstein, Paul Eliezer
wang-gillam, Andrea
Varghese, Anna M.
Ko, Andrew H.
Hendifar, Andrew Eugene
Ocean, Allyson J.
McGlothlin, Anna
Graves, Todd
Berry, Scott M.
Detry, Michelle A.
Fitzgerald, Mark
Bosse, Anna
Moravek, Cassadie
Feehan, Kelly
Howland, Carrie Meghann
Berry, Donald A.
Simeone, Diane M.
Picozzi, Vincent J.
Source :: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p675-675, 117p
Publication Year :: 2024

Full Text Access

Tools